BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2930204)

  • 1. [Antitumor effect of a new anthracycline derivative, MX2, against human glioma cells].
    Kuratsu J; Mihara Y; Kochi M; Takaki S; Ushio Y
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):399-403. PubMed ID: 2930204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
    Park SJ; Kaye AH; Hill JS
    J Clin Neurosci; 2000 Jan; 7(1):42-7. PubMed ID: 10847650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of MX2, a new morpholino anthracycline, against experimental brain tumors.
    Izumoto S; Arita N; Hayakawa T; Ohnishi T; Taki T; Yamamoto H; Ushio Y
    Anticancer Res; 1990; 10(3):735-9. PubMed ID: 2369088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro].
    Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Kitai R; Uno H; Kodera T
    No To Shinkei; 1995 Oct; 47(10):969-73. PubMed ID: 7577142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M; Komeshima N; Nakajima S; Tsuruo T
    Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics and antitumor activity of MX2, a new morpholino anthracycline in brain tumor intracerebral transplanted in rats].
    Kiya K; Ogasawara H; Fujita H; Sugiyama K; Kurisu K; Kawamoto K; Uozumi T; Shinkai H
    Gan To Kagaku Ryoho; 1993 Apr; 20(5):631-5. PubMed ID: 8470921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of MX-2, a morpholino anthracycline derivative, against human and rat glioma cells and experimental leptomeningeal tumors in rats].
    Izumoto S; Arita N; Ushio Y; Hayakawa T; Ohnishi T; Taki T; Yamamoto H; Oku Y; Mogami H; Komeshima N
    Gan To Kagaku Ryoho; 1988 May; 15(5):1765-9. PubMed ID: 3369870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
    Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
    Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination effect of hyperthermia and MX2 on cultured glioma cell lines].
    Mizumatsu S; Ono Y; Tamiya T; Matsumoto K; Ohmoto T; Furuta T
    Gan To Kagaku Ryoho; 1999 May; 26(6):789-95. PubMed ID: 10410148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antitumor effect of MX2, a new morpholino anthracycline, against malignant glioma cell lines and its subcellular distribution.
    Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Kitai R
    Neurosurgery; 1995 Sep; 37(3):471-6; discussion 476-7. PubMed ID: 7501112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of apoptosis in megakaryocytic leukemia cell lines by MX2, a morpholino anthracycline.
    Katsurada T; Adachi M; Kido H; Date M; Kishimoto Y; Yamanaka Y; Kimura T; Fukuhara S
    Exp Hematol; 1997 Sep; 25(10):1077-83. PubMed ID: 9293905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.
    Horichi N; Tapiero H; Sugimoto Y; Bungo M; Nishiyama M; Fourcade A; Lampidis TJ; Kasahara K; Sasaki Y; Takahashi T
    Cancer Res; 1990 Aug; 50(15):4698-701. PubMed ID: 2164445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of MX2, a new morpholino anthracycline, in CSF following intravenous injection].
    Yamamoto H; Arita N; Ohnishi T; Hiraga S; Izumoto S; Taki T; Higuchi M; Hayakawa T; Shinkai H
    Gan To Kagaku Ryoho; 1993 Jul; 20(9):1227-30. PubMed ID: 8333749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcellular localization and cellular pharmacokinetics of MX2, a new morpholino anthracycline in glioma cells using confocal laser scanning microscopy.
    Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Arai Y; Kitai R
    Neurol Res; 1994 Aug; 16(4):257-64. PubMed ID: 7984256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.
    Hu XF; Slater A; Rischin D; Kantharidis P; Parkin JD; Zalcberg J
    Br J Cancer; 1999 Feb; 79(5-6):831-7. PubMed ID: 10070877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Distribution and acute toxicity of a new morpholinoanthracycline, MX2, in normal rat brain after intra-arterial injection].
    Izumoto S; Arita N; Hayakawa T; Ohnishi T; Hiraga S; Taki T; Yamamoto H
    Gan To Kagaku Ryoho; 1991 Mar; 18(3):371-5. PubMed ID: 2003739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect and peritumoral brain edema formation in relation to MX2, ACNU, and doxorubicin therapy: a comparative analysis using rodent models of gliomas.
    Mima T; Mostafa MG; Mori K
    Neurol Res; 2000 Dec; 22(8):819-24. PubMed ID: 11149245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of menogaril against various malignant lymphoma cell lines and a human lymphoma xenograft in mice.
    Yoshida M; Fujioka A; Nakano K; Yuasa C; Toko T; Takeda S; Unemi N
    Anticancer Res; 1996; 16(5A):2875-9. PubMed ID: 8917401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand.
    Gourdeau H; McAlpine JB; Ranger M; Simard B; Berger F; Beaudry F; Farnet CM; Falardeau P
    Cancer Chemother Pharmacol; 2008 May; 61(6):911-21. PubMed ID: 17622531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.